Abstract： Objective： To observe the clinical effect of compound Xueshuantong capsules combined with laser photocoagulation for central retinal vein occlusion(CRVO). Methods：A total of 102 cases of CRVO patients were selected and divided into the control group and the treatment group according to the random number table method， with 51 cases in each group. The control group was treated with laser photocoagulation， and the treatment group was additionally treated with compound Xueshuantong capsules based on the treatment of the control group. Retinal hemodynamic indexes and the levels of soluble intercellular adhesion molecule- 1(ICAM- 1)， monocyte chemoattractant protein- 1(MCP- 1) and tumor necrosis factor-α(TNF-α) before and after treatment in the two groups were compared；the clinical effects and incidence of adverse reactions in the two groups were compared. Results：The total effective rate was 96.08% in the treatment group，higher than that of 82.35% in the control group(P＜0.05). After treatment， the pulsatility indexes(PI) and resistance indexes(RI) in the two groups were decreased when compared with those before treatment(P＜0.05)， and the end diastolic velocity(EDV) and peak systolic blood flow velocity(PSV) were increased when compared with those before treatment(P＜0.05)；PI and RI in the treatment group were lower than those in the control group(P＜0.05)；EDV and PSV were higher than those in the control group(P＜0.05). After treatment，the levels of ICAM-1，MCP-1 and TNF-α in the two groups were decreased when compared with those before treatment(P＜0.05)，and the levels of ICAM-1， MCP- 1 and TNF- α in the treatment group were lower than those in the control group(P＜0.05). The incidence of adverse reactions was 9.80% in the control group and 7.84% in the treatment group， there being no significant difference between the two groups(P＞0.05). Conclusion： The therapy of compound Xueshuantong capsules combined with laser photocoagulation for CRVO can enhance the clinical effect， improve the ocular blood circulation，and reduce the levels of ICAM- 1，MCP- 1 and TNF- α，with good safety.